Abstract
Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.
| Original language | English |
|---|---|
| Pages (from-to) | 333-339 |
| Number of pages | 7 |
| Journal | Seminars in Nephrology |
| Volume | 23 |
| Issue number | 4 |
| Publication status | Published - Jul 2003 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Nonimmunosuppressive therapy of membranous nephropathy. / Schieppati, Arrigo; Ruggenenti, Piero; Perna, Annalisa; Remuzzi, Giuseppe.
In: Seminars in Nephrology, Vol. 23, No. 4, 07.2003, p. 333-339.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nonimmunosuppressive therapy of membranous nephropathy
AU - Schieppati, Arrigo
AU - Ruggenenti, Piero
AU - Perna, Annalisa
AU - Remuzzi, Giuseppe
PY - 2003/7
Y1 - 2003/7
N2 - Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.
AB - Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.
UR - http://www.scopus.com/inward/record.url?scp=0042889562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042889562&partnerID=8YFLogxK
M3 - Article
C2 - 12923721
AN - SCOPUS:0042889562
VL - 23
SP - 333
EP - 339
JO - Seminars in Nephrology
JF - Seminars in Nephrology
SN - 0270-9295
IS - 4
ER -